Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q16637 (
SMA
)
8,107
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Proximal spinal muscular atrophy (SMA) is a common motor neuron disease caused by homozygous loss of the
survival motor neuron
gene (
SMN1
). SMN2, a nearly identical copy of the gene and present in all SMA patients, fails to provide protection from SMA, due to the disruption of an exonic splicing enhancer (ESE) by a single translationally silent nucleotide exchange, which causes alternative splicing of SMN2 exon 7. Identification of splicing factors that stimulate exon 7 inclusion and thereby produce sufficient amounts of full-length transcripts from the SMN2 gene is of great importance for therapy approaches. Here, by use of in vivo splicing assays, we identified the protein
hnRNP-G
and its paralogue RBM as two novel splicing factors that promote the inclusion of SMN2 exon 7. Moreover,
hnRNP-G
and RBM non-specifically bind RNA, but directly and specifically bind Htra2-beta1, an SR-like splicing factor which we have previously shown to stimulate inclusion of exon 7 through a direct interaction with the AG-rich ESE in SMN2 exon 7 pre-mRNA. By using deletion mutants of
hnRNP-G
, we show that the specific protein-protein interaction of
hnRNP-G
with Htra2-beta1 mediates the inclusion of SMN2 exon 7 rather than the non-specific interaction of
hnRNP-G
with SMN pre-mRNA. Additionally, we show for the first time that recombinant trans-acting splicing factors such as
hnRNP-G
and Htra2-beta1 are also effective on endogenous SMN2 transcripts and increase the endogenous SMN protein level. Finally, we suggest a model of how the exon 7 mRNA processing is regulated by the splicing factors identified so far.
...
PMID:hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1. 1216 65